Technology’s Role In Advancing Outcomes & Reducing The Cost Of Care For The SMI Population is starting in

Public Safety Notification On Exosome Products

On December 6, 2019, the U.S. Food and Drug Administration (FDA) released a public safety notice on exosome products due to multiple reports of serious adverse effects experienced by individuals in Nebraska who were treated with unapproved products marketed as containing exosomes. The public safety notice asserts that there are currently no FDA-approved exosome products and clinics offering such products outside of FDA's review process are taking advantage of consumers and pose significant harm . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: